{
    "clinical_study": {
        "@rank": "23199", 
        "arm_group": [
            {
                "arm_group_label": "1 Nintedanib (Reference)", 
                "arm_group_type": "Experimental", 
                "description": "single dose, oral with 240 ml water"
            }, 
            {
                "arm_group_label": "2 Nintedanib + Ketoconazole (Test)", 
                "arm_group_type": "Experimental", 
                "description": "Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water"
            }, 
            {
                "arm_group_label": "3 Nintedanib (Reference)", 
                "arm_group_type": "Experimental", 
                "description": "single dose, oral with 240 ml water"
            }, 
            {
                "arm_group_label": "4 Nintedanib + Ketoconazole (Test)", 
                "arm_group_type": "Experimental", 
                "description": "Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the current study is to investigate the relative bioavailability of a\n      single dose of nintedanib low or high dose with and without coadministration of ketoconazole\n      at steady state"
        }, 
        "brief_title": "Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1. healthy male subjects\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679613", 
            "org_study_id": "1199.161", 
            "secondary_id": "2012-001009-26"
        }, 
        "intervention": [
            {
                "arm_group_label": "3 Nintedanib (Reference)", 
                "description": "low or medium dose depending on pilot part", 
                "intervention_name": "Nintedanib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1 Nintedanib (Reference)", 
                "description": "low dose oral administration", 
                "intervention_name": "Nintedanib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2 Nintedanib + Ketoconazole (Test)", 
                "description": "oral administration", 
                "intervention_name": "Ketoconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2 Nintedanib + Ketoconazole (Test)", 
                "description": "low dose oral administration", 
                "intervention_name": "Nintedanib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "4 Nintedanib + Ketoconazole (Test)", 
                "description": "low or medium dose depending on pilot part", 
                "intervention_name": "Nintedanib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "4 Nintedanib + Ketoconazole (Test)", 
                "description": "oral administration", 
                "intervention_name": "Ketoconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ketoconazole"
        }, 
        "lastchanged_date": "May 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Biberach", 
                    "country": "Germany"
                }, 
                "name": "1199.161.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Relative Bioavailability of Nintedanib Given Alone and in Combination With Ketoconazole at Steady State in Healthy Male Volunteers (an Open-label, Randomised, Two-way Cross-over Clinical Phase I Study)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h postdose"
            }, 
            {
                "measure": "Maximum measured concentration of the analyte in plasma", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h postdose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679613"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration", 
            "safety_issue": "No", 
            "time_frame": "up to 72 h postdose"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}